Does combination of paricalcitol with cinacalcet in secondary hyperparathyroidism in hemodialysis treatment make sense?
نویسندگان
چکیده
منابع مشابه
Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
BACKGROUND Sclerostin is a paracrine acting factor, which is expressed in the osteocytes and articular chondrocytes. Sclerostin decreases the osteoblast-related bone formation through the inhibition of the Wnt/β-catenin pathway. Osteocytes also express the Calcium sensing receptor which is a target for cinacalcet. The aim of this study was to assess the influence of six-month cinacalcet treatme...
متن کاملThree months treatment with cinacalcet does not change plasma leptin concentration in hemodialysis patients with secondary hyperparathyroidism**
Introduction. Cinacalcet is a calcimimetic which increases the sensitivity of calcium sensing receptor (CaSR) to the serum calcium. CaSR is expressed among others also in adipocytes. Leptin is a hormone synthetized by the adipocytes which is involved in the regulation of energy balance and seems to be a marker of nutrition. Aim. The aim of this study was to assess the influence of 3 months trea...
متن کاملPartial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report
UNLABELLED INTRODUCTION In the treatment of secondary hyperparathyroidism of chronic kidney disease, calcimimetics - allosteric modulators of the calcium-sensing receptor - inhibit glandular hyperplasia and significantly reduce circulating parathyroid hormone levels. They have a major impact on the management of secondary hyperparathyroidism. CASE PRESENTATION We present the clinical case ...
متن کاملIntensification of Anemia by Secondary Hyperparathyroidism in Hemodialysis Patients
The excessive amounts of parathyroid hormone in secondary hyperparathyroidism (SHPTH) is suggested to interfere with normal erythropoiesis. In SHPTH, during chronic renal failure, due to the impairment of erythropoietin synthesis, this effect is more pronounced. In the present study the role of secondary hyperparathyroidism in the severity of anemia was evaluated in hemodialysis patients (n=3...
متن کاملParicalcitol for secondary hyperparathyroidism in renal transplantation.
Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d fo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Polish Archives of Internal Medicine
سال: 2017
ISSN: 1897-9483
DOI: 10.20452/pamw.4124